GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » PS Ratio

Arch Biopartners (TSXV:ARCH) PS Ratio : (As of May. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arch Biopartners's share price is C$1.69. Arch Biopartners's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00. Hence, Arch Biopartners's PS Ratio for today is .

The historical rank and industry rank for Arch Biopartners's PS Ratio or its related term are showing as below:

During the past 13 years, Arch Biopartners's highest PS Ratio was 1760.00. The lowest was 110.00. And the median was 475.00.

TSXV:ARCH's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.18
* Ranked among companies with meaningful PS Ratio only.

Arch Biopartners's Revenue per Sharefor the three months ended in Dec. 2023 was C$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00.

During the past 13 years, Arch Biopartners's highest 3-Year average Revenue per Share Growth Rate was 280.30% per year. The lowest was -49.20% per year. And the median was 1.05% per year.

Back to Basics: PS Ratio


Arch Biopartners PS Ratio Historical Data

The historical data trend for Arch Biopartners's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners PS Ratio Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 495.00 - - - -

Arch Biopartners Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arch Biopartners's PS Ratio

For the Biotechnology subindustry, Arch Biopartners's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's PS Ratio distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's PS Ratio falls into.



Arch Biopartners PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Arch Biopartners's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.69/0
=

Arch Biopartners's Share Price of today is C$1.69.
Arch Biopartners's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Arch Biopartners  (TSXV:ARCH) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Arch Biopartners PS Ratio Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners (TSXV:ARCH) Business Description

Traded in Other Exchanges
N/A
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.